Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors

被引:24
作者
Bhayye, S. S. [1 ]
Roy, K. [2 ]
Saha, A. [1 ]
机构
[1] Univ Calcutta, Dept Chem Technol, Kolkata, W Bengal, India
[2] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata, W Bengal, India
关键词
atom-based; 3D-QSAR; Parkinson's disease; HQSAR; activity cliff analysis; Dual targeting; Alzheimer's disease; MONOAMINE-OXIDASE-B; DRUG DESIGN; PARKINSONS-DISEASE; QSAR MODELS; VALIDATION; ALZHEIMERS; RECEPTORS; LIGANDS; ANALOGS; FUTURE;
D O I
10.1080/1062936X.2015.1136840
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Dual inhibition of A(2A) and MAO-B is an emerging strategy in neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD). In this study, atom-based three-dimensional quantitative structure-activity relationship (3D-QSAR) and hologram quantitative structure-activity relationship (HQSAR) models were generated with benzothiazine and deazaxanthine derivatives. Based on activity against A(2A) and MAO-B, two statistically signi?cant 3D-QSAR models (r(2) = 0.96, q(2) = 0.76 and r(2) = 0.91, q(2) = 0.63) and HQSAR models (r(2) = 0.93, q(2) = 0.68 and r(2) = 0.97, q(2) = 0.58) were developed. In an activity cliff analysis, structural outliers were identified by calculating the Mahalanobis distance for a pair of compounds with A(2A) and MAO-B inhibitory activities. The generated 3D-QSAR and HQSAR models, activity cliff analysis, molecular docking and dynamic studies for dual target protein inhibitors provide key structural scaffolds that serve as building blocks in designing drug-like molecules for neurodegenerative diseases.
引用
收藏
页码:183 / 202
页数:20
相关论文
共 40 条
[1]  
[Anonymous], 2015, GLID 6 7
[2]  
[Anonymous], 2015, CANV 2 4
[3]  
[Anonymous], 2015, MAESTR 10 2
[4]  
[Anonymous], 2015, LIGPREP 3 4
[5]  
[Anonymous], 2014, DESMOND MOLECULAR DY
[6]  
[Anonymous], SYB 7 2
[7]   Potentiation of Ligand Binding through Cooperative Effects in Monoamine Oxidase B [J].
Bonivento, Daniele ;
Milczek, Erika M. ;
McDonald, G. Reid ;
Binda, Claudia ;
Holt, Andrew ;
Edmondson, Dale E. ;
Mattevi, Andrea .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (47) :36849-36856
[8]   Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems [J].
Brichta, Lars ;
Greengard, Paul ;
Flajolet, Marc .
TRENDS IN NEUROSCIENCES, 2013, 36 (09) :543-554
[9]   Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors [J].
Chavan, Swapnil ;
Bhayye, Sagar ;
Sobhia, M. Elizabeth .
MOLECULAR DIVERSITY, 2011, 15 (04) :979-987
[10]   8-(3-chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism [J].
Chen, JF ;
Steyn, S ;
Staal, R ;
Petzer, JP ;
Xu, K ;
Van der Schyf, CJ ;
Castagnoli, K ;
Sonsalla, PK ;
Castagnoli, N ;
Schwarzschild, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) :36040-36044